2019
The 9th International Symposium on Physical, Molecular, Cellular, and Medical Aspects of Auger Processes, August 2019, University of Oxford, UK
Dr. Reilly presented in the symposium with the title Cancer treatment in the adjuvant context with Auger Electron (AE) – emitting radiotherapeutic agents. Zhongli Cai presented her research work on Cellular Dosimetry of 197(m)Hg and 111In -- Comparison of potency and identification of the cell membrane as an important target for Dose Deposition.
Dr. Reilly presented in the symposium with the title Cancer treatment in the adjuvant context with Auger Electron (AE) – emitting radiotherapeutic agents. Zhongli Cai presented her research work on Cellular Dosimetry of 197(m)Hg and 111In -- Comparison of potency and identification of the cell membrane as an important target for Dose Deposition.
Great Lakes Symposium, July 2019, University at Buffalo, USA
Luke Kwon presented in the Great Lakes Symposium and got the best podium presenter award. Congratulations!
Luke Kwon presented in the Great Lakes Symposium and got the best podium presenter award. Congratulations!
NSERC Collaborative Research and Training Experience Program (CREATE)
Polymer Nanoparticles for Drug Delivery (PoND) Program 2nd Annual Research Day, June 2019,
Quebec City, Canada.
Dr Reilly presented in the feature seminar with the title Advancing Novel Radiopharmaceuticals to Phase 1 Clinical Trial – A Roadmap Leading to Health Canada Approval. Valerie Facca presented a poster with the title Preclinical Characterization of 111In-Panitumumab Radioimmunoconjugatesfor Auger Electron Radiotherapy of Triple Negative Breast Cancer.
Polymer Nanoparticles for Drug Delivery (PoND) Program 2nd Annual Research Day, June 2019,
Quebec City, Canada.
Dr Reilly presented in the feature seminar with the title Advancing Novel Radiopharmaceuticals to Phase 1 Clinical Trial – A Roadmap Leading to Health Canada Approval. Valerie Facca presented a poster with the title Preclinical Characterization of 111In-Panitumumab Radioimmunoconjugatesfor Auger Electron Radiotherapy of Triple Negative Breast Cancer.
|
Canadian Society for Pharmaceutical Sciences (CSPS) symposium, May 2019, Vancouver, Canada
Noor Alsaden and Constantine Georgiou presented in the CSPS symposium with Noor's poster presentation, Trastuzumab-DM1 affects the vasculature of tumour microenvironment causing enhanced delivery of 64Cu-NOTA-pertuzumab Fab visualized by MicroPET/CT imaging (Noor Al-saden, Azza Al-Mahrouki, Zhongli Cai, and Raymond Reilly) selected as the the first place poster winner. Congratulations! |
|
2018
|
Annual Congress of the European Association of Nuclear Medicine
October 2018, Düsseldorf, Germany Y. Kwon, Z. Cai, A. Al-Mahrouki, D. Scollard, R. M. Reilly Engineering and Characterization of a Human Tumour Xenograft Mouse Model Heterogeneous for HER2 and EGFR to Assess Tumour Delivery of Bispecific Radioimmunoconjugates (bsRICs). [poster presentation] V. J. Facca, N. Al-saden, A. Ku, R. M. Reilly Development of 99mTc-Labeled Pertuzumab Fab as a Molecular Imaging Agent for HER2 Positive Tumour Xenografts Using MicroSPECT/CT. [oral presentation] N. Al-saden, Z. Cai, C. Chan, R. Reilly Cytotoxicity In Vitro and Anti-Tumour Effects In Vivo of Trastuzumab-DM1 (T-DM1) are Correlated with HER2 Expression Level and Tumour Uptake of 89Zr-DFOTrastuzumab-DM1 Assessed by PET. [oral presentation] A. Ku, C. Chan, D. Hedley, L. Ailles, S. Bratman, D. Scollard, R. Reilly MicroSPECT/CT Imaging of Patient-Derived EGFR-Positive Tumour Xenografts with Technetium-99m Labeled Panitumumab Fab Fragments. [oral presentation] A. Ku, C. Chan, J. Adams, S. Sidhu, R. Reilly Feasibility of MicroSPECT/CT Imaging of RNF-43 Mutant Pancreatic Cancer Xenografts Overexpressing Frizzled-5 with Technetium-99m-Labeled Anti-Frizzled 5/8 Fab Fragments. [poster presentation] |
|
University Health Network/Radiation Medicine Program
September 2018, Toronto, Canada
Dr Raymond Reilly, Amanda Boyle and Sadaf Aghevlian presented in the Radiation Medicine Program Rounds with the title Approaches and Experience in the Development of Radioimmunotherapeutic Agents for Pancreatic Cancer.
September 2018, Toronto, Canada
Dr Raymond Reilly, Amanda Boyle and Sadaf Aghevlian presented in the Radiation Medicine Program Rounds with the title Approaches and Experience in the Development of Radioimmunotherapeutic Agents for Pancreatic Cancer.
Graduate Research in Progress (GRIP)
June 2018, Toronto, Canada
The Graduate Research in Progress (GRIP) is an annual symposium that allows graduate students at the Graduate Department of Pharmaceutical Science-University of Toronto an opportunity to share their research findings to fellow students, faculty and industry professionals.
Congratulations to Anthony Ku for winning the poster award.
June 2018, Toronto, Canada
The Graduate Research in Progress (GRIP) is an annual symposium that allows graduate students at the Graduate Department of Pharmaceutical Science-University of Toronto an opportunity to share their research findings to fellow students, faculty and industry professionals.
Congratulations to Anthony Ku for winning the poster award.
2017
|
Annual Congress of the European Association of Nuclear Medicine
October 2017, Vienna, Austria C. Chan, J. Seki, R. Kwong, R. M. Reilly. First application of radionuclide labeling and imaging studies to assess the pharmaceutical stability of reconstituted trastuzumab (Herceptin) stored under correct or incorrect conditions. [poster presentation]. Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik , Raymond M. Reilly Panitumumab Modified With Metal Chelating Polymers (MCPs) For Dual Labeling With 111In and 177Lu as a Potential Theranostic For Pancreatic Cancer. [oral presentation]. |
|
|
Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 Annual Meeting
June 2017, Denver, Colorado, USA Zhongli Cai, Priscilla Lai, Simmyung Yook, Yijie Lu, Mitchell A. Winnik, Jean-Philippe Pignol, Raymond M. Reilly 111In-labeled EGFR-targeting gold nanoparticles for treatment of lung metastases from triple negative breast cancer. [oral presentation] Anthony Ku, Conrad Chan, Deborah Scollard & Raymond M. Reilly Chemical linkage of His6-containing peptides to Panitumumab antibody Fab fragments to enable labeling with 99mTc (I) – tricarbonyl complex. [oral Presentation] |
|
2016
|
Annual Congress of the European Association of Nuclear Medicine (EANM’16)
October 2016, Barcelona, Spain Vanessa A. Prozzo, Conrad Chan and Raymond M. Reilly Formulation of a GMP Quality Kit for the Preparation of 111In-DTPA-NLS Trastuzumab Injection: An Auger Electron-Emitting Theranostic Agent for HER2-Positive Breast Cancer. [e-poster presentation] Noor Alsaden, Conrad Chan, R. Reilly 89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer. [e-poster presentation] |
|
|
The first annual research symposium for the Centre for Pharmaceutical Oncology
October 2016, Toronto, Canada Luke (Yongkyu) Kwon, Zhongli Cai, Deborah Scollard, and Raymond M. Reilly Overcoming Receptor Heterogeneity of PET and Radioimmunotherapy (RIT) of HER2 Positive Breast Cancer using Bispecific Radioimmunoconjugates (bsRICs) [poster presentation] Priscilla Lai, Zhongli Cai, Jean-Philippe Pignol, David Jaffray and Raymond Reilly A nanodepot system for local placement and controlled release of radiolabeled gold nanoparticles (AUNPs). [poster presentation] Vanessa A. Prozzo, Conrad Chan and Raymond M. Reilly Formulation of a GMP Quality Kit for the Preparation of 111In-DTPA-NLS Trastuzumab Injection: An Auger Electron-Emitting Theranostic Agent for HER2-Positive Breast Cancer. [poster presentation] Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik , Raymond M. Reilly Panitumumab Modified With Metal Chelating Polymers (MCPs) For Dual Labeling With 111In and 177Lu as a Potential Theranostic For Pancreatic Cancer. [oral presentation]. Noor Alsaden, Conrad Chan, R. Reilly 89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer. [poster presentation, first place poster winner] Amanda J. Boyle; Yijie Lu; David W. Hedley; Mitchell Winnik; Raymond M. Reilly. Metal-chelating polymers (MCPs) harboring multiple pendant PEG2K chains linked to panitumumab F(ab')2 fragments for microPET/CT imaging of patient-derived pancreatic cancer xenografts in mice. [poster presentation] |
|
14th Imaging Network Ontario Symposium
March 2016, Toronto, Canada.
Noor Alsaden, Conrad Chan, R. Reilly
89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer. [Oral presentation-New Imaging Approaches].
Vanessa A. Prozzo, Conrad Chan and Raymond M. Reilly
Formulation of a GMP Quality Kit for the Preparation of 111In-DTPA-NLS-Trastuzumab Injection: An Auger Electron-Emitting Theranostic Agent for HER2-Positive Breast Cancer. [Poster presentation)
March 2016, Toronto, Canada.
Noor Alsaden, Conrad Chan, R. Reilly
89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer. [Oral presentation-New Imaging Approaches].
Vanessa A. Prozzo, Conrad Chan and Raymond M. Reilly
Formulation of a GMP Quality Kit for the Preparation of 111In-DTPA-NLS-Trastuzumab Injection: An Auger Electron-Emitting Theranostic Agent for HER2-Positive Breast Cancer. [Poster presentation)
2015
|
Canadian Cancer Research Conference
November 2015 Montreal, Canada Noor Alsaden, Conrad Chan, R. Reilly 89Zr-Trastuzumab-DM1: A Novel Probe for Positron-Emission Tomography (PET) Imaging of the Delivery of T-DM1 (Kadcyla) to HER2-Positive Breast Cancer. [Poster presentation]. |
|
|
Annual Congress of the European Association of Nuclear Medicine (EANM’15)
October 2015 Hamburg, Germany C. Chan, H. Fonge, K. Lam, R. Reilly Auger Electron Radioimmunotherapy with 111In-Bn-DTPA-Nimotuzumab Inhibits the Growth of EGFR-Positive Human Breast Cancer Tumours in Mice at Doses that are Non-Toxic to Normal Tissues. [Poster walk presentation]. Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik , Raymond M. Reilly Panitumumab Modified With Metal Chelating Polymers (MCPs) For Dual Labeling With 111In and 177Lu as a Potential Theranostic For Pancreatic Cancer. [Poster presentation]. |
|
|
World Molecular Imaging Congress (WMIC)
September 2015, Honolulu, USA Yongkyu Luke Kwon, Deborah Scollard, and Raymond M. Reilly. MicroPET/CT Imaging of Co-expressed EGFR and HER2 in Breast Cancer Tumour Xenografts in Mice using Bispecific Radioimmunoconjugates (bsRICs). [Poster presentation]. |
|
|
International Nanomedicine Conference
July 2015, Sydney, Australia Simmyung Yook, Yijie Lu, Jenny Jooyoung Jeong, Zhongli Cai, Jean-Philippe Pignol, Mitchell A. Winnik and Raymond M. Reilly Optimization of the stability of metal chelating polymer (MCP)-gold nanoparticles (AuNPs) complexes for radioimmunotherapy. [oral presentation]. |
|
Graduate Research in Progress (GRIP)
June 2015, Toronto, Canada
The Graduate Research in Progress (GRIP) is an annual symposium that allows graduate students at the Graduate Department of Pharmaceutical Science-University of Toronto an opportunity to share their research findings to fellow students, faculty and industry professionals.
June 2015, Toronto, Canada
The Graduate Research in Progress (GRIP) is an annual symposium that allows graduate students at the Graduate Department of Pharmaceutical Science-University of Toronto an opportunity to share their research findings to fellow students, faculty and industry professionals.
Canadian Society of Pharmaceutical Sciences
May 2015, Toronto, Canada.
Karen Lam, Raymond M. Reilly
64Cu-NOTA-pertuzumab F(ab')2 fragments, a second-generation probe
for PET imaging of the response of HER2-positive breast cancer to
trastuzumab (Herceptin). [poster presentation].
Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik , Raymond M. Reilly
Panitumumab modified with metal chelating polymers (MCPs) for dual
labeling with 111In and 177Lu as a potential theranostic for pancreatic
cancer. [poster presentation].
Simmyung Yook, Jenny Jooyoung Jeong, Zhongli Cai, Yijie Lu, Jean-Philippe
Pignol, Mitchell A. Winnik and Raymond M. Reilly.
177Lu-labeled and dual-receptor targeted radiation nanomedicine for
simultaneous targeting of HER2 and EGFR on breast cancer cells.
[poster presentation and oral presentation].
May 2015, Toronto, Canada.
Karen Lam, Raymond M. Reilly
64Cu-NOTA-pertuzumab F(ab')2 fragments, a second-generation probe
for PET imaging of the response of HER2-positive breast cancer to
trastuzumab (Herceptin). [poster presentation].
Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik , Raymond M. Reilly
Panitumumab modified with metal chelating polymers (MCPs) for dual
labeling with 111In and 177Lu as a potential theranostic for pancreatic
cancer. [poster presentation].
Simmyung Yook, Jenny Jooyoung Jeong, Zhongli Cai, Yijie Lu, Jean-Philippe
Pignol, Mitchell A. Winnik and Raymond M. Reilly.
177Lu-labeled and dual-receptor targeted radiation nanomedicine for
simultaneous targeting of HER2 and EGFR on breast cancer cells.
[poster presentation and oral presentation].
3rd ESTRO Forum
April 2015, Barcelona, Spain.
Priscilla Lai, Eli Lechtman, Shahram Mashouf, Raymond Reilly, Gregory
Czarnota, Jean-Philippe Pignol.
Design of gold nanoparticle brachytherapy seeds for permanent breast
seed implantation (PBSI). [poster presentation].
April 2015, Barcelona, Spain.
Priscilla Lai, Eli Lechtman, Shahram Mashouf, Raymond Reilly, Gregory
Czarnota, Jean-Philippe Pignol.
Design of gold nanoparticle brachytherapy seeds for permanent breast
seed implantation (PBSI). [poster presentation].
American Association of Cancer Research (AACR) Annual Meeting
April 2015, Philadelphia, USA.
Ghislaine Ngo Ndjock Mbong , Yijie Lu , Conrad Chan , Zhongli Cai , Mitchell
A. Winnik , Raymond Reilly.
Tumor and normal tissue localization of trastuzumab-modified with a metal
chelating polymer for Auger electron radioimmunotherapy in HER2-positive
xenografts. [poster presentation].
April 2015, Philadelphia, USA.
Ghislaine Ngo Ndjock Mbong , Yijie Lu , Conrad Chan , Zhongli Cai , Mitchell
A. Winnik , Raymond Reilly.
Tumor and normal tissue localization of trastuzumab-modified with a metal
chelating polymer for Auger electron radioimmunotherapy in HER2-positive
xenografts. [poster presentation].
13th Imaging Network Ontario Symposium
March 2015, London, Canada.
Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik,
Raymond Reilly.
Panitumumab modified with metal chelating polymers (MCPs) for dual labeling
with 111In and 177Lu as a potential theranostic for pancreatic cancer.
[poster presentation and oral presentation].
Luke Kwon, Deborah Scollard and Raymond Reilly.
MicroPET/CT imaging of co-expressed EGFR and HER2 in breast cancer
tumour xenografts in mice using bispecific radioimmunoconjugate (bsRICs).
[poster presentation, first place poster winner].
March 2015, London, Canada.
Sadaf Aghevlian, Yijie Lu, Conrad Chan, David W Hedley, Mitchell A. Winnik,
Raymond Reilly.
Panitumumab modified with metal chelating polymers (MCPs) for dual labeling
with 111In and 177Lu as a potential theranostic for pancreatic cancer.
[poster presentation and oral presentation].
Luke Kwon, Deborah Scollard and Raymond Reilly.
MicroPET/CT imaging of co-expressed EGFR and HER2 in breast cancer
tumour xenografts in mice using bispecific radioimmunoconjugate (bsRICs).
[poster presentation, first place poster winner].
2014
Annual Congress of the European Association of Nuclear Medicine (EANM’14)
October 2014, Gothenburg, Sweden.
Bergstrom, D., Leyton, J.V, Zereshkian, A., Cai, Z., Chan, C., Reilly, R.M. 111In-NLS-CSL360 – An Auger electron radioimmunotheraputic agent for acute myeloid leukemia targeting the leukemia stem cell population. [Poster Presentation]
Yook, S., Cai, Z., Lu, Y., Pignol, J.P., Winnik, M.A., Reilly, R.M. A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice. [Oral Presentation] Eckert & Ziegler Award
Cai, Z., Chattopadhyay, N., Yang, K., Kwon, Y.L., Yook, S., Pignol J.P., Reilly, R.M. Intratumourally-administered 111In-labeled and HER2-targeted gold nanoparticles for localized Auger electron radiotherapy of breast cancer xenografts in athymic mice. {Poster Presentation].
Cai, Z., Yook, S., Lu, Y., Winnik, M.A., Pignol, J.P., Reilly, R.M. 177Lu-labeled and trastuzumab-conjugated gold nanoparticles exhibit multivalent receptor binding, increased DNA double-strand breaks and dramatically increased cytotoxicity towards HER2-positive breast cancer cells compared to 177Lu-labeled trastuzumab. [Poster Presentation].
October 2014, Gothenburg, Sweden.
Bergstrom, D., Leyton, J.V, Zereshkian, A., Cai, Z., Chan, C., Reilly, R.M. 111In-NLS-CSL360 – An Auger electron radioimmunotheraputic agent for acute myeloid leukemia targeting the leukemia stem cell population. [Poster Presentation]
Yook, S., Cai, Z., Lu, Y., Pignol, J.P., Winnik, M.A., Reilly, R.M. A comparison of EGFR-targeted and non-targeted 177Lu-labeled gold nanoparticles (AuNPs) for localized radiation treatment of breast cancer xenografts in athymic mice. [Oral Presentation] Eckert & Ziegler Award
Cai, Z., Chattopadhyay, N., Yang, K., Kwon, Y.L., Yook, S., Pignol J.P., Reilly, R.M. Intratumourally-administered 111In-labeled and HER2-targeted gold nanoparticles for localized Auger electron radiotherapy of breast cancer xenografts in athymic mice. {Poster Presentation].
Cai, Z., Yook, S., Lu, Y., Winnik, M.A., Pignol, J.P., Reilly, R.M. 177Lu-labeled and trastuzumab-conjugated gold nanoparticles exhibit multivalent receptor binding, increased DNA double-strand breaks and dramatically increased cytotoxicity towards HER2-positive breast cancer cells compared to 177Lu-labeled trastuzumab. [Poster Presentation].
European Symposium on Radiopharmacy and Radiopharmaceuticals
April 2014, Pamplona, Spain.
Ngo Ndjock Mbong,G., Lu, Y., Winnik, M.A., Reilly, R.M. Metal-chelating polymer-conjugated trastuzumab labeled to high specific activity with indium-111 is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of Auger electrons. [Poster Presentation]. Included in Highlights of the symposium
April 2014, Pamplona, Spain.
Ngo Ndjock Mbong,G., Lu, Y., Winnik, M.A., Reilly, R.M. Metal-chelating polymer-conjugated trastuzumab labeled to high specific activity with indium-111 is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of Auger electrons. [Poster Presentation]. Included in Highlights of the symposium
American Association for Cancer Research (AACR) Annual Meeting
April 2014, San Diego, USA.
Boyle A.J., Hedley D.W., S. Sidhu, Winnik M.A., Reilly R.M. 64Cu-NOTA-panitumumab F(ab’)2 fragments for PET/CT imaging of pancreatic cancer. [Poster Presentation]
April 2014, San Diego, USA.
Boyle A.J., Hedley D.W., S. Sidhu, Winnik M.A., Reilly R.M. 64Cu-NOTA-panitumumab F(ab’)2 fragments for PET/CT imaging of pancreatic cancer. [Poster Presentation]
Imaging Network Ontario (ImNO) Symposium
March 2014, Toronto, Canada.
Boyle A.J. and Reilly, R.M. PET theranostics for pancreatic cancer. [Poster Presentation]. 1st Place Poster Award
March 2014, Toronto, Canada.
Boyle A.J. and Reilly, R.M. PET theranostics for pancreatic cancer. [Poster Presentation]. 1st Place Poster Award
2013
San Antonio Breast Cancer Symposium 2013 (SABCS)
December 2013, San Antonio, Texas, USA.
Yook S., Cai Z., Lu Y., Pignol J.P., Winnik M.A., Reilly R.M. Synthesis and characterization of EGFR antibody-mediated tumor targeted “gold nanobombs” for treatment of locally advanced breast cancer. [Poster Presentation]
Ngo Ndjock Mbong,G., Lu Y., Chan C., Cai Z., Winnik M.A., and Reilly R.M. Metal chelating polymer (MCP)-conjugated trastuzumab labeled to high specific activity (SA) with 111In is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of Auger electrons. [Poster Presentation]
December 2013, San Antonio, Texas, USA.
Yook S., Cai Z., Lu Y., Pignol J.P., Winnik M.A., Reilly R.M. Synthesis and characterization of EGFR antibody-mediated tumor targeted “gold nanobombs” for treatment of locally advanced breast cancer. [Poster Presentation]
Ngo Ndjock Mbong,G., Lu Y., Chan C., Cai Z., Winnik M.A., and Reilly R.M. Metal chelating polymer (MCP)-conjugated trastuzumab labeled to high specific activity (SA) with 111In is cytotoxic to trastuzumab-sensitive and resistant breast cancer cells through the emission of Auger electrons. [Poster Presentation]
Annual Congress of the European Association of Nuclear Medicine (EANM'13)
October 2013, Lyon, France.
Chan C., Bergstrom D., Lam K., Done S., Cai Z., Reilly R.M. In Vitro targeting of trastuzumab-resistant breast cancer cells and in vivo biodistribution and acute toxicity studies using a high specific radioactivity Auger electron radioimmunotherapeutic agent composed of trastuzumab and PAMAM dendrimer displaying multiple DTPA chelators for 111In. [Poster Walk Presentation]
October 2013, Lyon, France.
Chan C., Bergstrom D., Lam K., Done S., Cai Z., Reilly R.M. In Vitro targeting of trastuzumab-resistant breast cancer cells and in vivo biodistribution and acute toxicity studies using a high specific radioactivity Auger electron radioimmunotherapeutic agent composed of trastuzumab and PAMAM dendrimer displaying multiple DTPA chelators for 111In. [Poster Walk Presentation]
SNMMI-AACR Molecular Imaging in Cancer Therapy Conference
March 2013, San Diego, CA, USA
Leyton, J.V., Williams, B., Keating, A., Dick, J.E., Minden, M., Reilly, R.M. 111In-CSL360 modified with nuclear localization signal containing peptides specific for the leukemic stem cell phenotype CD123+CD131- for leukemia detection and Auger electron radioimmunotherapy. [Oral Presentation]
Razumienko, E., Dryden, L., Scollard, D., Reilly, R.M. Novel bispecific 111In-labeled radioimmunoconjugates (bsRICs) for SPECT/CT imaging of EGFR and HER2 receptors in breast cancer. [Poster Presentation]
March 2013, San Diego, CA, USA
Leyton, J.V., Williams, B., Keating, A., Dick, J.E., Minden, M., Reilly, R.M. 111In-CSL360 modified with nuclear localization signal containing peptides specific for the leukemic stem cell phenotype CD123+CD131- for leukemia detection and Auger electron radioimmunotherapy. [Oral Presentation]
Razumienko, E., Dryden, L., Scollard, D., Reilly, R.M. Novel bispecific 111In-labeled radioimmunoconjugates (bsRICs) for SPECT/CT imaging of EGFR and HER2 receptors in breast cancer. [Poster Presentation]
2012
World Molecular Imaging Conference (WMIC)
November 2012, Dublin, Ireland.
Razumienko E., Reilly R.M. Novel 111In-labeled immunoconjugates bispecific for EGFR and HER2 for molecular imaging of breast cancer. [Poster Presentation]
November 2012, Dublin, Ireland.
Razumienko E., Reilly R.M. Novel 111In-labeled immunoconjugates bispecific for EGFR and HER2 for molecular imaging of breast cancer. [Poster Presentation]
Annual Congress of the European Association of Nuclear Medicine (EANM'12)
October 2012, Milan, Italy
Leyton J.V., Gao C., Dick J.E., Minden M., Reilly R.M. Auger electron radioimmunotherapy of acute myelogenous leukemia using novel 111In-labeled chimeric mAb 360 reduces CD123+/CD131- leukemic stem cell population in NOD/SCID mice. [Oral Presentation]
October 2012, Milan, Italy
Leyton J.V., Gao C., Dick J.E., Minden M., Reilly R.M. Auger electron radioimmunotherapy of acute myelogenous leukemia using novel 111In-labeled chimeric mAb 360 reduces CD123+/CD131- leukemic stem cell population in NOD/SCID mice. [Oral Presentation]
European Symposium on Radiopharmacy and Radiopharmaceuticals
April 2012, Nantes, France.
Lam, K., Chan, C., Scollard, D., Reilly, R.M. A kit for the preparation of 111In-pertuzumab for a Phase I clinical trial of imaging early response to trastuzumab (Herceptin) in breast cancer. [Poster Presentation]
April 2012, Nantes, France.
Lam, K., Chan, C., Scollard, D., Reilly, R.M. A kit for the preparation of 111In-pertuzumab for a Phase I clinical trial of imaging early response to trastuzumab (Herceptin) in breast cancer. [Poster Presentation]
Canadian Society of Pharmaceutical Sciences (CSPS) Annual Conference
June 2012, Toronto, Canada
Chattopadhyay, N., Fonge, H., Cai, Z., Scollard, D., Pignol, J-P., Lechtman, E., Reilly, R.M. MicroSPECT/CT imaging: advancing our understanding of the biodistribution of molecularly targeted nanoparticles for cancer therapy. [Poster Presentation]
Ngo Ndjock Mbong,G., Lu, Y., Liu, P., Winnik, M., Reilly, R.M. Enhanced Auger electron radioimmunotherapy of breast cancer using trastuzumab modified with metal-chelating polymers for complexing indium-111. [Poster Presentation]
Razumienko E., Scollard, D., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation]
June 2012, Toronto, Canada
Chattopadhyay, N., Fonge, H., Cai, Z., Scollard, D., Pignol, J-P., Lechtman, E., Reilly, R.M. MicroSPECT/CT imaging: advancing our understanding of the biodistribution of molecularly targeted nanoparticles for cancer therapy. [Poster Presentation]
Ngo Ndjock Mbong,G., Lu, Y., Liu, P., Winnik, M., Reilly, R.M. Enhanced Auger electron radioimmunotherapy of breast cancer using trastuzumab modified with metal-chelating polymers for complexing indium-111. [Poster Presentation]
Razumienko E., Scollard, D., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation]
Imaging Network of Ontario (ImNO) Annual Conference
February 2012, Toronto, Canada.
Razumienko, E. Scollard, D., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation]
Chattopadhyay, N., Cai, Z., Scollard, D., Pignol, J.P., Reilly, R.M. MicroSPECT/CT imaging: A novel approach to understand in vivo trafficking of HER-2 targeted and non-targeted gold nanoparticles. [Poster Presentation]
February 2012, Toronto, Canada.
Razumienko, E. Scollard, D., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation]
Chattopadhyay, N., Cai, Z., Scollard, D., Pignol, J.P., Reilly, R.M. MicroSPECT/CT imaging: A novel approach to understand in vivo trafficking of HER-2 targeted and non-targeted gold nanoparticles. [Poster Presentation]
2011
Society of Nuclear Medicine and Molecular Imaging (SNMMI)
June 2011, San Antonio, TX, USA.
Gao, C., Leyton, J., Schimmer, A., Reilly, R.M. 111In-NLS-CSL360, a potent Auger electron-emitting radiotherapeutic agent for CD123-positive leukemic stem cells. [Oral Presentation]
Boyle, A., Liu, P., Lu, Y., Weinrich, D., Winnik, M., Reilly, R.M. Streptavidin (SA)-trastuzumab (Tmab) Fab for linking biotinylated (Bi) multi-chelation site polymers (MCPs) for amplifying the delivery of 111In to HER2-positive breast cancer cells. [Poster Presentation]
June 2011, San Antonio, TX, USA.
Gao, C., Leyton, J., Schimmer, A., Reilly, R.M. 111In-NLS-CSL360, a potent Auger electron-emitting radiotherapeutic agent for CD123-positive leukemic stem cells. [Oral Presentation]
Boyle, A., Liu, P., Lu, Y., Weinrich, D., Winnik, M., Reilly, R.M. Streptavidin (SA)-trastuzumab (Tmab) Fab for linking biotinylated (Bi) multi-chelation site polymers (MCPs) for amplifying the delivery of 111In to HER2-positive breast cancer cells. [Poster Presentation]
Annual Congress of the European Association of Nuclear Medicine (EANM'11)
October 2011, Birmingham, U.K.
Chan, C., Cai, Z., Reilly, R. Novel Auger electron radioimmunotherapeutic agent for HER2-positive breast cancercells composed of trastuzumab and PAMAM dendrimer displaying multiple DTPA chelators for 111In. [Poster Walk Presentation] Included in Highlights of the Congress
October 2011, Birmingham, U.K.
Chan, C., Cai, Z., Reilly, R. Novel Auger electron radioimmunotherapeutic agent for HER2-positive breast cancercells composed of trastuzumab and PAMAM dendrimer displaying multiple DTPA chelators for 111In. [Poster Walk Presentation] Included in Highlights of the Congress
2011 Canadian Cancer Research Conference
November 2011, Toronto, Canada.
Lam, K., Scollard, D., Chan, C., Reilly, R.M. A kit for preparation of 111In-pertuzumab for imaging early response to trastuzumab (Herceptin) in breast cancer. [Poster Presentation] Trainee Award.
Razumienko, E.J., Scollard D.A., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation] Trainee Award.
November 2011, Toronto, Canada.
Lam, K., Scollard, D., Chan, C., Reilly, R.M. A kit for preparation of 111In-pertuzumab for imaging early response to trastuzumab (Herceptin) in breast cancer. [Poster Presentation] Trainee Award.
Razumienko, E.J., Scollard D.A., Reilly, R.M. Novel bispecific radioimmunoconjugates for SPECT/CT imaging of HER2 and HER3 in breast cancer. [Poster Presentation] Trainee Award.
7th International Symposium on the Physical, Molecular, Cellular and Medical Aspects of Auger Electrons
August 2011, Julich, Germany.
Cai Z., Chattopadhyay N., Kwon Y., Lechtman E., Keller B., Reilly, R.M., Pignol J.P. Investigation of the effects of cellular and subcellular location of gold nanoparticles on cellular dose enhancemen factors using Monte Carlo simulation. [Poster Presentation]
Cai, Z., Kwon, Y. L., Chattopadhyay, N., Reilly, R. M. Cellular Dosimetry of 64Cu Using Monte Carlo N-Particle (MCNP) Computer Code: Comparison with Analytic Methods. [Poster Presentation]
August 2011, Julich, Germany.
Cai Z., Chattopadhyay N., Kwon Y., Lechtman E., Keller B., Reilly, R.M., Pignol J.P. Investigation of the effects of cellular and subcellular location of gold nanoparticles on cellular dose enhancemen factors using Monte Carlo simulation. [Poster Presentation]
Cai, Z., Kwon, Y. L., Chattopadhyay, N., Reilly, R. M. Cellular Dosimetry of 64Cu Using Monte Carlo N-Particle (MCNP) Computer Code: Comparison with Analytic Methods. [Poster Presentation]
Breast Cancer Imaging: State-of-the-Art 2011 Conference. National Institutes of Health.
April 2011, Bethesda, MD, USA
Fonge, H., Fasih, A., Leyton, J., Allen, C., Reilly, R,M. MicroSPECT/CT imaging of EGFR-positive tumor xenografts in athymic mice with 111In-Bn-DTPA-nimotuzumab with/without nuclear localization sequence (NLS) peptide modification. [Oral Presentation]
April 2011, Bethesda, MD, USA
Fonge, H., Fasih, A., Leyton, J., Allen, C., Reilly, R,M. MicroSPECT/CT imaging of EGFR-positive tumor xenografts in athymic mice with 111In-Bn-DTPA-nimotuzumab with/without nuclear localization sequence (NLS) peptide modification. [Oral Presentation]
American Association for Cancer Research Nano in Cancer: Linking Chemistry, Biology, and Clinical Applications In Vivo.
January 2011, Miami, FL, USA
Chattopadhyay N., Cai, Z., Keller, B., Lechtman, E., Pignol, J.P., Bendayan, R., Reilly, R.M. Targeted breast cancer radiation therapy with gold nanoparticles. [Poster Presentation]
January 2011, Miami, FL, USA
Chattopadhyay N., Cai, Z., Keller, B., Lechtman, E., Pignol, J.P., Bendayan, R., Reilly, R.M. Targeted breast cancer radiation therapy with gold nanoparticles. [Poster Presentation]
2010
American Society of Hematology Annual Meeting
December 2010, Orlando, FL, USA.
Leyton, J., Gao, C., Hu, M., Dick, J.E., Minden, M.D., Reilly, R.M. MicroSPECT/CT imaging of human leukemia engraftment in NOD-SCID mice using 111In-labeled 7G3 anti-CD123 antibodies. [Oral Presentation] Trainee Award.
December 2010, Orlando, FL, USA.
Leyton, J., Gao, C., Hu, M., Dick, J.E., Minden, M.D., Reilly, R.M. MicroSPECT/CT imaging of human leukemia engraftment in NOD-SCID mice using 111In-labeled 7G3 anti-CD123 antibodies. [Oral Presentation] Trainee Award.
American Association for Cancer Research Annual Meeting
April 2010, Washington, DC, USA
Razumienko, E., Reilly, R.M. Novel bispecific 111In-Labeled immunoconjugates (bsICs) for imaging HER2/HER3 heterodimerization in breast cancer. [Poster Presentation]
Fasih, A., Tikhomirov, I., Reilly, R.M. 111In-NLS-Nimotuzumab - A potent Auger electron-emitting radiotherapeutic agent for EGFR-overexpressing breast cancer. [Poster Presentation]
April 2010, Washington, DC, USA
Razumienko, E., Reilly, R.M. Novel bispecific 111In-Labeled immunoconjugates (bsICs) for imaging HER2/HER3 heterodimerization in breast cancer. [Poster Presentation]
Fasih, A., Tikhomirov, I., Reilly, R.M. 111In-NLS-Nimotuzumab - A potent Auger electron-emitting radiotherapeutic agent for EGFR-overexpressing breast cancer. [Poster Presentation]
